The proposed mechanism is that downregulated EZH2 expression unleashes pro-inflammatory functions in tumor-infiltrating Tregs cells, which promotes anti-cancer immunity as well as tumor elimination, boosts the recruitment and function of CD8+ and CD4+ effector T cells, and thus remodels the tumor microenvironment [60]. This evidence concerns the gene EZH2 and cancer.